Importantly, all anti‐CD38 antibodies currently used in the clinic for multiple myeloma do not target the catalytic site, but rather an allosteric site, and are potentially cytotoxic through mechanisms such as antibody‐dependent cell‐mediated cytotoxicity (ADCC) or complement‐dependent cytotoxicity (CDC). Here, CD38 is linked to AL amyloidosis.